A practical approach to immunotherapy of hepatocellular carcinoma using T cells redirected against hepatitis B virus

Molecular Therapy Nucleic Acids

Volumn 2, Issue AUG, 2013, Pages e114-

  Koh, Sarene ^a,b   Shimasaki, Noriko ^c   Suwanarusk, Rossarin ^d   Ho, Zi Zong ^a   Chia, Adeline ^a   Banu, Nasirah ^a   Howland, Shanshan Wu ^d   Ong, Alice Soh Meoy ^d   Gehring, Adam J ^e   Stauss, Hans ^f   Renia, Laurent ^d   Sällberg, Matti ^b   Campana, Dario ^c   Bertoletti, Antonio ^a,g  

^a AGENCY FOR SCIENCE   (Singapore)

^b KAROLINSKA INSTITUTE   (Sweden)

^c NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^d AGENCY FOR SCIENCE   (Singapore)

^e SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f ROYAL FREE HOSPITAL   (United Kingdom)

^g DUKE NUS MEDICAL SCHOOL   (Singapore)

Author keywords

Hepatitis B virus; Hepatocellular carcinoma; MRNA electroporation; TCR gene therapy

Indexed keywords

T LYMPHOCYTE RECEPTOR; VIRUS MESSENGER RNA; VIRUS VECTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CELL THERAPY; CONTROLLED STUDY; CYTOKINE PRODUCTION; ELECTROPORATION; HEPATITIS B VIRUS; HUMAN; HUMAN CELL; LIVER CELL CARCINOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; T LYMPHOCYTE; TUMOR SEEDING; TUMOR XENOGRAFT;

EID: 84884227487     PISSN: None     EISSN: 21622531     Source Type: Journal    
DOI: 10.1038/mtna.2013.43     Document Type: Article

References (35)

1. Parkin, DM, Bray, F, Ferlay, J and Pisani, P (2001). Estimating the world cancer burden: Globocan 2000. Int J Cancer 94: 153-156. (Pubitemid 32911406)
2. El-Serag, HB (2012). Epidemiology of viral hepatitis and hepatocellular carcinoma. Gastroenterology 142: 1264-1273.e1.
3. Sung, WK, Zheng, H, Li, S, Chen, R, Liu, X, Li, Y et al. (2012). Genome-wide survey of recurrent HBV integration in hepatocellular carcinoma. Nat Genet 44: 765-769.
4. Brechot, C, Pourcel, C, Louise, A, Rain, B and Tiollais, P (1980). Presence of integrated hepatitis B virus DNA sequences in cellular DNA of human hepatocellular carcinoma. Nature 286: 533-535. (Pubitemid 10017698)
5. Edman, JC, Gray, P, Valenzuela, P, Rall, LB and Rutter, WJ (1980). Integration of hepatitis B virus sequences and their expression in a human hepatoma cell. Nature 286: 535-538. (Pubitemid 10017699)
6. Llovet, JM, Burroughs, A and Bruix, J (2003). Hepatocellular carcinoma. Lancet 362: 1907-1917. (Pubitemid 37518510)
7. Straathof, KC, Bollard, CM, Popat, U, Huls, MH, Lopez, T, Morriss, MC et al. (2005). Treatment of nasopharyngeal carcinoma with Epstein-Barr virus-specific T lymphocytes. Blood 105: 1898-1904. (Pubitemid 40731770)
8. Rooney, CM, Smith, CA, Ng, CY, Loftin, SK, Sixbey, JW, Gan, Y et al. (1998). Infusion of cytotoxic T cells for the prevention and treatment of Epstein-Barr virus-induced lymphoma in allogeneic transplant recipients. Blood 92: 1549-1555. (Pubitemid 28406858)
9. Gehring, AJ, Ho, ZZ, Tan, AT, Aung, MO, Lee, KH, Tan, KC et al. (2009). Profile of tumor antigen-specific CD8 T cells in patients with hepatitis B virus-related hepatocellular carcinoma. Gastroenterology 137: 682-690.
10. June, CH, Blazar, BR and Riley, JL (2009). Engineering lymphocyte subsets: tools, trials and tribulations. Nat Rev Immunol 9: 704-716.
11. Park, TS, Rosenberg, SA and Morgan, RA (2011). Treating cancer with genetically engineered T cells. Trends Biotechnol 29: 550-557.
12. Gehring, AJ, Xue, SA, Ho, ZZ, Teoh, D, Ruedl, C, Chia, A et al. (2011). Engineering virusspecific T cells that target HBV infected hepatocytes and hepatocellular carcinoma cell lines. J Hepatol 55: 103-110.
13. Ando, K, Moriyama, T, Guidotti, LG, Wirth, S, Schreiber, RD, Schlicht, HJ et al. (1993). Mechanisms of class I restricted immunopathology. A transgenic mouse model of fulminant hepatitis. J Exp Med 178: 1541-1554. (Pubitemid 23318433)
14. Maini, MK, Boni, C, Lee, CK, Larrubia, JR, Reignat, S, Ogg, GS et al. (2000). The role of virus-specific CD8(+) cells in liver damage and viral control during persistent hepatitis B virus infection. J Exp Med 191: 1269-1280. (Pubitemid 30227116)
15. Bertoletti, A and Maini, MK (2000). Protection or damage: a dual role for the virus-specific cytotoxic T lymphocyte response in hepatitis B and C infection? Curr Opin Microbiol 3: 387-392. (Pubitemid 30640363)
16. Marshall, E (2002). Gene therapy a suspect in leukemia-like disease. Science 298: 2002-2003.
17. Hacein-Bey-Abina, S, Garrigue, A, Wang, GP, Soulier, J, Lim, A, Morillon, E et al. (2008). Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1. J Clin Invest 118: 3132-3142.
18. Recchia, A, Bonini, C, Magnani, Z, Urbinati, F, Sartori, D, Muraro, S et al. (2006). Retroviral vector integration deregulates gene expression but has no consequence on the biology and function of transplanted T cells. Proc Natl Acad Sci USA 103: 1457-1462. (Pubitemid 43191187)
19. Hunziker, L, Klenerman, P, Zinkernagel, RM and Ehl, S (2002). Exhaustion of cytotoxic T cells during adoptive immunotherapy of virus carrier mice can be prevented by B cells or CD4+ T cells. Eur J Immunol 32: 374-382. (Pubitemid 34173329)
20. Antony, PA, Piccirillo, CA, Akpinarli, A, Finkelstein, SE, Speiss, PJ, Surman, DR et al. (2005). CD8+ T cell immunity against a tumor/self-antigen is augmented by CD4+ T helper cells and hindered by naturally occurring T regulatory cells. J Immunol 174: 2591-2601. (Pubitemid 40279672)
21. Ho, WY, Yee, C and Greenberg, PD (2002). Adoptive therapy with CD8(+) T cells: it may get by with a little help from its friends. J Clin Invest 110: 1415-1417. (Pubitemid 35396912)
22. Robbins, PF, Dudley, ME, Wunderlich, J, El-Gamil, M, Li, YF, Zhou, J et al. (2004). Cutting edge: persistence of transferred lymphocyte clonotypes correlates with cancer regression in patients receiving cell transfer therapy. J Immunol 173: 7125-7130. (Pubitemid 39628146)
23. Zhou, J, Dudley, ME, Rosenberg, SA and Robbins, PF (2005). Persistence of multiple tumor-specific T-cell clones is associated with complete tumor regression in a melanoma patient receiving adoptive cell transfer therapy. J Immunother 28: 53-62. (Pubitemid 40075938)
24. Berger, C, Jensen, MC, Lansdorp, PM, Gough, M, Elliott, C and Riddell, SR (2008). Adoptive transfer of effector CD8+ T cells derived from central memory cells establishes persistent T cell memory in primates. J Clin Invest 118: 294-305.
25. Gattinoni, L, Klebanoff, CA, Palmer, DC, Wrzesinski, C, Kerstann, K, Yu, Z et al. (2005). Acquisition of full effector function in vitro paradoxically impairs the in vivo antitumor efficacy of adoptively transferred CD8+ T cells. J Clin Invest 115: 1616-1626. (Pubitemid 40814670)
26. Klebanoff, CA, Gattinoni, L, Torabi-Parizi, P, Kerstann, K, Cardones, AR, Finkelstein, SE et al. (2005). Central memory self/tumor-reactive CD8+ T cells confer superior antitumor immunity compared with effector memory T cells. Proc Natl Acad Sci USA 102: 9571-9576. (Pubitemid 40981722)
27. van Loenen, MM, de Boer, R, Amir, AL, Hagedoorn, RS, Volbeda, GL, Willemze, R et al. (2010). Mixed T cell receptor dimers harbor potentially harmful neoreactivity. Proc Natl Acad Sci USA 107: 10972-10977.
28. Zhao, Y, Moon, E, Carpenito, C, Paulos, CM, Liu, X, Brennan, AL et al. (2010). Multiple injections of electroporated autologous T cells expressing a chimeric antigen receptor mediate regression of human disseminated tumor. Cancer Res 70: 9053-9061.
29. Llovet, JM, Schwartz, M and Mazzaferro, V (2005). Resection and liver transplantation for hepatocellular carcinoma. Semin Liver Dis 25: 181-200. (Pubitemid 40781071)
30. Faria, LC, Gigou, M, Roque-Afonso, AM, Sebagh, M, Roche, B, Fallot, G et al. (2008). Hepatocellular carcinoma is associated with an increased risk of hepatitis B virus recurrence after liver transplantation. Gastroenterology 134: 1890-9; quiz 2155. (Pubitemid 351783254)
31. Rabinovich, PM, Komarovskaya, ME, Ye, ZJ, Imai, C, Campana, D, Bahceci, E et al. (2006). Synthetic messenger RNA as a tool for gene therapy. Hum Gene Ther 17: 1027-1035. (Pubitemid 46076744)
32. Shimasaki, N, Fujisaki, H, Cho, D, Masselli, M, Lockey, T, Eldridge, P et al. (2012). A clinically adaptable method to enhance the cytotoxicity of natural killer cells against B-cell malignancies. Cytotherapy 14: 830-840.
33. Li, L, Liu, LN, Feller, S, Allen, C, Shivakumar, R, Fratantoni, J et al. (2010). Expression of chimeric antigen receptors in natural killer cells with a regulatory-compliant non-viral method. Cancer Gene Ther 17: 147-154.
34. Belnoue, E, Guettier, C, Kayibanda, M, Le Rond, S, Crain-Denoyelle, AM, Marchiol, C et al. (2004). Regression of established liver tumor induced by monoepitopic peptidebased immunotherapy. J Immunol 173: 4882-4888. (Pubitemid 39387769)
35. Rénia, L, Rodrigues, MM and Nussenzweig, V (1994). Intrasplenic immunization with infected hepatocytes: a mouse model for studying protective immunity against malaria pre-erythrocytic stage. Immunology 82: 164-168 (Pubitemid 24234554)